Loading
Every dated change on the records linked to Non-Hodgkin lymphoma (all types), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.
Median overall survival 19.
Median investigator-assessed progression-free survival 22.
Progression-free survival adjusted hazard ratio 0.
Median progression-free survival 31.
ENRICH, 397 patients: adjusted progression-free survival hazard ratio 0.69, driven by the comparison against R-CHOP (0.37) rather than against bendamustine-rituximab (0.91). ECHELON-3 and POLARGO gave transplant-ineligible relapsed diffuse large B-cell lymphoma two more options with a survival benefit.
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
In the follicular lymphoma cohort, objective response 80.
4-year PFS 94.
Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0.
Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)
Overall response 69 against 46 per cent (p = 0.
2-year PFS 92% vs 83%, HR 0.
Glofitamab and epcoritamab, off-the-shelf CD20 x CD3 antibodies, approved for relapsed large B-cell lymphoma.
R/R follicular lymphoma after ≥2 lines (accelerated)
Complete response in 69.
Median progression-free survival 80.
BELINDA: median event-free survival 3.0 months in both arms, with a 52-day median interval from leukapheresis to infusion and 25.9 per cent of the CAR-T group progressing by week 6 against 13.8 per cent of the comparator group.
High-grade B-cell lymphoma with MYC and BCL2 rearrangements becomes an entity of its own and the T-follicular-helper lymphomas are grouped by origin rather than appearance. A second classification published the same year disagrees on several names.
The fifth edition of the WHO classification and the International Consensus Classification were published within months of each other. They agree about most entities and differ about several names and boundaries, which is why a report may give a disease a name that a trial protocol does not recognise.
EFS HR 1.
2-year PFS 76.
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
PhasED-seq uses several mutations carried on one DNA fragment, which lymphoma genomes supply because of somatic hypermutation, and finds residual disease in a further 25% of participants called negative by the previous method.
Zanubrutinib did not significantly increase the complete or very good partial response rate over ibrutinib, but had markedly less cardiovascular and other toxicity; approved for Waldenström macroglobulinaemia in 2021.
Objective response in 73 per cent and complete response in 53 per cent of 256 evaluable patients, with grade 3 or worse cytokine release syndrome in 2 per cent.
High objective and complete response rates with durable remissions in mantle cell lymphoma after BTK inhibitor failure; approved in July 2020.
A probabilistic classifier assigns a lymphoma to one of seven genetic subtypes and shows each shares a pathogenesis with a particular indolent or extranodal lymphoma. No randomised trial has yet assigned treatment by it.
TRANSCEND NHL 001: objective response 73 per cent and complete response 53 per cent in 256 evaluable patients, with grade 3 or worse cytokine release syndrome in 2 per cent. SHINE then gained 28 months of progression-free survival in older mantle cell lymphoma with no survival benefit.
No difference in progression-free survival (hazard ratio 0.
Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.
Three-year progression-free survival 96 per cent with four cycles of R-CHOP plus two extra rituximab doses, non-inferior to six cycles, with roughly a quarter fewer adverse events.
A pivotal single-arm study supporting the approval of tisagenlecleucel in relapsed or refractory large B-cell lymphoma after two or more lines.
Median progression-free survival 10.
FLYER: three-year progression-free survival 96 per cent with four cycles of R-CHOP in young favourable disease, non-inferior to six. PHOENIX: ibrutinib improved event-free survival under 60 (hazard ratio 0.579) and worsened it over 60, raising serious adverse events from 38.2 to 63.4 per cent.
BCL2 G101V, found at progression in 7 of 15 paired patients and in none at study entry, lowers drug affinity about 180-fold and is detectable months before clinical relapse.
First-line stage III/IV Hodgkin lymphoma with AVD
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.
Complete response at 120 weeks 48 percent with rituximab-lenalidomide against 53 percent with rituximab-chemotherapy (p 0.
Ten-year progression-free survival 59 against 41 per cent when systemic therapy followed radiotherapy (hazard ratio 0.
Two large series read large B-cell lymphoma as four and five genetically defined groups, MCD, BN2, N1 and EZB among them, with different outcomes after immunochemotherapy.
Chapuy's five clusters from 304 tumours and Schmitz's four subtypes from 574; Wright's LymphGen tool in 2020 extended them to seven and made per-patient classification possible. None has yet changed a first-line treatment.
Relapsed/refractory large B-cell lymphoma ≥2 lines
Three-year progression-free survival 80.
Progression-free survival hazard ratio 0.
Five-year event-free survival 68 per cent with chlorambucil and rituximab against 51 and 50 per cent for either alone, with five-year overall survival about 90 per cent in all three arms.
Four-year event-free survival 79 against 61 per cent (p = 0.
Overall response 88 percent and complete remission 70 percent with risk-stratified sequential treatment; three-year response duration 82 percent; median overall survival 6.
Progression-free survival hazard ratio 0.
High objective and complete response rates in refractory large B-cell lymphoma with durable remissions in a large minority; approved in October 2017.
Axicabtagene ciloleucel approved for relapsed large B-cell lymphoma after two or more lines.
One-year overall survival 87.
Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 percent after whole-brain radiotherapy and 75 percent after autologous transplant.
Scherer showed circulating tumour DNA predicts outcome at diagnosis, classifies cell of origin from plasma, beats imaging for residual disease and distinguishes follicular lymphomas that will transform from those that will not.
Relapse without CD19 turns out to combine deletion, exon 2 mutation and selection for an alternatively spliced transcript that skips the epitope and still partly works, which is why a standard sequencing test can call the gene normal.
Nivolumab produces an objective response in 20 of 23 heavily pre-treated patients, most of whom had already failed autologous transplant and brentuximab vedotin.
Casulo: 19 per cent of 588 patients progressed within two years of first-line R-CHOP, with five-year overall survival of 50 against 90 per cent and an index-adjusted hazard ratio of 6.44.
Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation
4 Gy was not non-inferior to 24 Gy for local control: five-year local progression-free rate 89.
BTK C481S in five of six patients with acquired ibrutinib resistance and PLCG2 gain-of-function mutations in two, which is why the non-covalent inhibitors exist.
A single substitution in 67 to 68% of cases, specific to the tumour cells, with the accompanying TET2 mutations also present in normal blood cells, which places this lymphoma as a growth out of clonal haematopoiesis.
Agreed at the International Conference on Malignant Lymphoma, it made PET-CT the standard staging test for lymphomas that take up the tracer, restricted the A and B symptom suffixes to Hodgkin lymphoma, and removed routine bone marrow biopsy from the staging of Hodgkin lymphoma.
Relapsed Hodgkin lymphoma and systemic ALCL
Overall response 79 per cent and complete response 45 per cent after two cycles, one-year overall survival 55 per cent, with grade 4 neutropenia in 92 per cent.
SMILE reached an overall response of 79 per cent in 38 patients with a disease that resists anthracyclines; PRIMA raised three-year progression-free survival from 57.6 to 74.9 per cent, and at nine years the medians were 10.5 against 4.1 years with no survival difference.
An oncogenic MYD88 substitution is found in 29% of activated B-cell-like lymphomas; in the same period CREBBP and EP300 inactivation is found in about 39% of diffuse large B-cell and 41% of follicular lymphoma, and KMT2D in 32% and 89%, which makes lymphoma a disease of chromatin and not only of signalling.
CLL, indolent NHL, multiple myeloma (national approvals)
Two findings in one year: activated B-cell-like lymphoma depends on continuous B-cell receptor signalling through BTK, which is the rationale for every BTK inhibitor; and Hodgkin lymphoma and mediastinal large B-cell lymphoma amplify the locus carrying both PD-1 ligands and JAK2, which is the rationale for checkpoint blockade there.
Gain-of-function substitutions at a single tyrosine in the SET domain are found in 21.7% of germinal-centre large B-cell lymphomas and 7.2% of follicular lymphomas, and absent from the activated subtype; tazemetostat follows.
Complete response 40 against 25 per cent (p = 0.
JCOG9801, 118 patients: complete response 40 against 25 per cent for VCAP-AMP-VECP over biweekly CHOP, three-year overall survival 24 against 13 per cent, grade 4 thrombocytopenia 74 against 17 per cent.
Initial management of plasma uric acid in paediatric patients with leukaemia, lymphoma or solid tumours at risk of tumour lysis (adults added 2009)
Rosenwald profiled 240 biopsies, found germinal-centre, activated and type 3 subgroups and built a 17-gene survival predictor independent of the International Prognostic Index; Hans reproduced the split in 2004 with three ordinary stains, giving five-year survival of 76 against 34 per cent.
Relapsed follicular lymphoma; first antibody approved for cancer
Anti-CD20 rituximab for relapsed follicular lymphoma; added to CHOP it raised cure rates in diffuse large B-cell lymphoma.